spironolactone has been researched along with Secondary Hyperparathyroidism in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hyperaldosteronism due to klotho deficiency results in vascular calcification, which can be mitigated by spironolactone treatment." | 4.90 | Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. ( Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Kienreich, K; Kraigher-Krainer, E; März, W; Mrak, P; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Toplak, H; Verheyen, N, 2014) |
| " The recent introduction of a novel, long-acting testosterone formulation (testosterone undecanoate) which only requires one intramuscular injection every 3 months, together with the already available hydroalcoholic testosterone gels, appear to be promising alternatives to the previous standard substitution therapy for male hypogonadism." | 4.83 | [The latest developments in endocrinology 2004/2005]. ( Fottner, C; Weber, MM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomaschitz, A | 1 |
| Ritz, E | 1 |
| Pieske, B | 1 |
| Rus-Machan, J | 1 |
| Kienreich, K | 1 |
| Verheyen, N | 1 |
| Gaksch, M | 1 |
| Grübler, M | 1 |
| Fahrleitner-Pammer, A | 1 |
| Mrak, P | 1 |
| Toplak, H | 1 |
| Kraigher-Krainer, E | 1 |
| März, W | 1 |
| Pilz, S | 1 |
| Khouzam, RN | 1 |
| Dishmon, DA | 1 |
| Farah, V | 1 |
| Flax, SD | 1 |
| Carbone, LD | 1 |
| Weber, KT | 1 |
| Fottner, C | 1 |
| Weber, MM | 1 |
2 reviews available for spironolactone and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Bone Density; Bone Diseases; Calcium; Cardiovascular Diseases; | 2014 |
[The latest developments in endocrinology 2004/2005].
Topics: Adrenal Gland Neoplasms; Adult; Bone Density Conservation Agents; Chronic Kidney Disease-Mineral and | 2006 |
1 other study available for spironolactone and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Female; Furosemide; Heart Failure; | 2006 |